Daymark Wealth Partners’s Corcept Therapeutics CORT Stock Holding History

Daymark Wealth Partners’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$227K	Buy	+1,972	New	+$212K	0.01%	794

Other funds holding CORT

Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Daymark Wealth Partners's CORT Position: Q3 2026 in Review

Daymark Wealth Partners opened a new position in Corcept Therapeutics (CORT) in Q3 2026: 1,972 shares worth $227K. The stake represents 0.01% of the portfolio and ranks #794 among its holdings.

236 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

Daymark Wealth Partners held 1,972 shares of Corcept Therapeutics worth $227K as of Q3 2026.
Corcept Therapeutics was a new Daymark Wealth Partners position in Q3 2026.
Corcept Therapeutics made up 0.01% of Daymark Wealth Partners's portfolio in Q3 2026, its #794 holding.
236 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Daymark Wealth Partners's 13F filing for Q3 2026, filed 4 Nov 2026.